文献速递产科母胎医学妇科

打开潘多拉魔盒:异常遗传携带者筛查与终身随访需求

Opening Pandora's box: abnormal genetic carrier screening and need for lifetime follow-up.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-11-28

本研究在纽约市学术医疗中心对2018至2021年接受扩展性携带者筛查的1184名育龄女性进行回顾性队列分析,发现14.2%携带具有母体表型表达潜能的突变,其中23人被建议专科就诊,仅17%实际完成转诊。作者认为随着扩展性携带者筛查普及,需解决咨询与随访负担。

要点

  • 扩展性携带者筛查中14.2%患者携带具有母体表型表达潜能的突变。
  • 23名被建议专科就诊的患者中仅4名(17%)完成推荐转诊。
  • 作者认为需解决扩展性携带者筛查带来的咨询与随访负担。

核心结论

  • 14.2%接受扩展性携带者筛查的患者被识别为具有母体表型表达潜能的突变携带者。
  • 23名被建议特定专科就诊的患者中仅17.4%遵循建议。
  • 作者认为随着扩展性携带者筛查普及,咨询与随访负担必须得到解决。

研究设计与样本

  • 经机构审查委员会批准的描述性回顾性队列研究,在纽约市学术医疗中心进行。
  • 2018至2021年由提供者(包括妇产科医生、母胎医学医生和遗传咨询师)向育龄女性提供普遍扩展性携带者筛查。
  • 筛查面板包含283个与遗传性疾病相关的基因,其中20个(7.1%)为常染色体隐性条件,21个(7.4%)为X连锁条件。
  • 通过电子病历评估患者分娩后至少1年的医疗利用率。

主要发现

  • 1184名患者中168名(14.2%)被识别为具有母体表型表达潜能的突变携带者。
  • 168名携带者中156名(93%)为妊娠期,12名(7%)为孕前。
  • 143名(85%)为常染色体隐性特质携带者,22名(13%)为X连锁条件携带者,3名(2%)同时携带常染色体隐性和X连锁条件。
  • 168名携带者中132名(78.6%)接受了遗传咨询。
  • 最常见的杂合突变依次为镰状细胞特质(25.6%)、地中海贫血(α和/或β)特质(14.2%)、因子XI缺乏(4.7%)、营养不良性大疱性表皮松解症(4.2%)和Alport综合征(4.1%)。

临床怎么用

  • 作者认为随着扩展性携带者筛查实施普及,将识别出更多对自身有临床风险的母体携带者,咨询与随访负担必须得到解决。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Expanded carrier screening (ECS) is rising in popularity because of its application in a diverse population, its decreasing cost, and efficiency.1 However, it has traditionally been used to assess fetal risk. The next generation sequencing ECS panel offered at our academic medical center consists of 283 genes associated with hereditary disorders. Of those, 20 (7.1%) are autosomal recessive conditions, notable for variable expression of the clinical phenotype in heterozygous carriers, which may increase maternal risk for malignancy, bleeding, cardiovascular, or rheumatologic disease. Another 21 (7.4%) are X-linked conditions. We aimed to evaluate the prevalence of variants that have a potential for maternal phenotypic expression and whether identification of specific variants prompted patients to pursue further care in our health system, namely comprehensive genetic counseling and further healthcare consults when recommended. STUDY DESIGN: An institutional review board-approved descriptive retrospective cohort study was performed in a New York City academic medical center at which reproductive aged women were offered universal ECS from 2018 to 2021 by their provider, inclusive of obstetrician-gynecologists, maternal-fetal medicine physicians, and genetic counselors. Pretest counseling was performed by the ordering provider. Patients found to carry mutations with the potential for maternal phenotypic expression were contacted by genetic counselors regarding their clinical risks. In addition, patients who were carriers for factor XI deficiency, Bernard Soulier syndrome, ataxia telangectesia, fumarase deficiency, Nijmegen breakage syndrome, Duchenne muscular dystrophy, and familial hypercholesterolemia were advised to seek specialized healthcare pertaining to their clinical risk. The genetic counseling summary was placed in the electronic medical records (EMRs) so that the primary provider could view the findings. Through our EMRs, we evaluated the rates of healthcare uptake among these patients for at least 1 year after delivery. RESULTS: In total, 168 of 1184 (14.2%) patients were identified as carriers of mutations with a potential for maternal phenotypic expression. Of these, 156 (93%) were pregnant and 12 (7%) were preconception. Of those patients, 143 (85%) were carriers of autosomal recessive traits (Figure 1), whereas 22 of 168 (13%) patients were carriers of X-linked conditions (Figure 2) and 3 of 168 (2%) patients carried both autosomal recessive traits and X-linked conditions. Of these carriers, 132 of 168 (78.6%) patients underwent genetic counseling. The most common heterozygous mutations were sickle cell trait (25.6%), thalassemia (alpha and/or beta) trait (14.2%), factor XI deficiency (4.7%), dystrophic epidermolysis bullosa (4.2%), and Alport syndrome (4.1%). Two patients were diagnosed as homozygous carriers of nonclassical congenital adrenal hyperplasia. During the study period, 23 of 168 (13.6%) patients were heterozygous for specific pathogenic variants (inclusive of factor XI, Bernard Soulier syndrome, ataxia telangectesia, fumarase deficiency, Nijmegen breakage syndrome, Duchenne muscular dystrophy, and familial hypercholesterolemia) and were advised to seek specialized healthcare pertaining to these findings. Of these, 20 (87.0%) received genetic counseling with standardized recommendations, however, only 4 of 23 (17%) patients pursued the recommended referrals during our study period. CONCLUSION: This study described the follow-up rates among patients identified as carriers of conditions with the potential for maternal phenotypic expression using ECS. We observed that 14.2% of patients who underwent ECS were identified as carriers of genetic mutations with the potential for maternal phenotypic expression, and of the 23 who were recommended specific care because a pathogenic variant was identified, only 17.4% of patients followed the recommendations. We believe that as ECS implementation becomes widespread, more maternal carriers with clinical risk to themselves will be identified. Therefore, as we open this Pandora's box, the burden of counseling and follow-up must be addressed.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Strauss TS, Boniferro E, Brockhoff E, et al. Opening Pandora's box: abnormal genetic carrier screening and need for lifetime follow-up. Am J Obstet Gynecol MFM. 2022. PMID: 36455867. doi:10.1016/j.ajogmf.2022.100820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。